Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative ...

Induced pluripotent stem cells (iPSCs) are characterized by the ability ... Cells were grown to 80% to 90% confluent at the time of adding CytoTune®-IPS Sendai Reprogramming reagent in order ...

From drug discovery to organoid modeling of disease, stem cells are increasingly being used in research as a vital tool for scientific investigation. Due to the specialized nature of stem cells, their ...

When iPS cells (plated in 96-well plates) were 80–90% confluent, the cells were washed ... Wells containing cells with pluripotent morphology that were likely to have been derived from a single ...

Induced pluripotent stem cells (iPSCs) represent a significant breakthrough in the fields of cell therapy and regenerative medicine. The distinct ability of iPSCs to differentiate into practically ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC ... cell types, live-cell imaging assays to simplify assessment of microglia motility and morphology ...

When generating induced pluripotent stem cells (iPSCs) for use in downstream applications, it is commonplace to perform initial checks for key attributes such as viability and pluripotency. This ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic, a cell therapy platform provider that partners with therapeutic developers to ensure cell therapies can achieve their full potential, has ...

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics ...

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell BrightPath Bio (Tokyo Stock Exchange Growth ...